Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

aTyr Pharma, Inc. ATYR

Healthcare  —  Biotechnology
0.31 (0.03) (8.82%) as of 25 Sep
Market cap
$31.4M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

aTyr Pharma, Inc. (ATYR) Business Profile

Updated before January 2025

Company Overview

aTyr Pharma, Inc. (NASDAQ: ATYR) is a biotherapeutics company headquartered in San Diego, California. Founded in 2005, the company focuses on discovering and developing innovative medicines based on novel biological pathways. aTyr specializes in leveraging the therapeutic potential of tRNA synthetase biology, a unique area of science that has the potential to address a wide range of diseases. The company was co-founded by Paul Schimmel, Ph.D., a renowned scientist in the field of tRNA synthetase biology, and John Mendlein, Ph.D., a seasoned biotech entrepreneur. The current CEO and President of aTyr Pharma is Dr. Sanjay Shukla, who has been instrumental in driving the company’s strategic direction and clinical advancements.

Core Business Segments

aTyr Pharma operates primarily in the biopharmaceutical sector, focusing on the development of innovative therapeutics. The company’s core business segments include:

1. Neurological and Inflammatory Diseases

aTyr’s lead therapeutic candidate, efzofitimod (ATYR1923), is a first-in-class immunomodulator designed to treat severe inflammatory diseases. Efzofitimod targets neuropilin-2 (NRP2), a receptor that plays a key role in immune regulation. The drug is currently being developed for interstitial lung diseases (ILDs), including pulmonary sarcoidosis, a rare and debilitating condition.

2. tRNA Synthetase Biology

aTyr is a pioneer in exploring the therapeutic potential of tRNA synthetase biology. The company’s research focuses on extracellular functions of tRNA synthetases, which have been shown to play critical roles in immune modulation and tissue homeostasis. This platform has the potential to generate a pipeline of novel therapeutics for a variety of diseases.

3. Preclinical Pipeline

In addition to efzofitimod, aTyr is advancing a preclinical pipeline of therapeutic candidates targeting NRP2 and other pathways. These programs aim to address unmet medical needs in oncology, fibrosis, and other serious conditions.

Business Model

aTyr Pharma’s business model is centered on the discovery, development, and commercialization of innovative therapeutics. The company integrates cutting-edge science with a focus on addressing unmet medical needs. Revenue generation is primarily achieved through:

  • Collaborations and Partnerships: aTyr has established strategic partnerships with leading pharmaceutical companies and academic institutions to advance its research and development efforts. These collaborations provide funding, expertise, and access to resources.
  • Licensing Agreements: The company licenses its proprietary technologies and therapeutic candidates to partners, generating milestone payments and royalties.
  • Clinical Development: aTyr invests heavily in clinical trials to bring its therapeutic candidates to market, with the goal of achieving regulatory approval and commercial success.

Strategic Direction

aTyr Pharma is committed to advancing its pipeline of innovative therapeutics and expanding its scientific platform. Key strategic priorities include:

  • Clinical Development of Efzofitimod: The company is focused on advancing efzofitimod through late-stage clinical trials for pulmonary sarcoidosis and exploring its potential in other interstitial lung diseases.
  • Expansion of tRNA Synthetase Platform: aTyr aims to unlock the full potential of tRNA synthetase biology by identifying new therapeutic targets and developing novel drug candidates.
  • Global Partnerships: The company seeks to establish additional collaborations with pharmaceutical companies and research institutions to accelerate the development and commercialization of its therapies.
  • Sustainability Goals: aTyr is committed to conducting its operations in an environmentally and socially responsible manner, with a focus on reducing its carbon footprint and promoting diversity and inclusion.

Competitive Landscape

aTyr Pharma operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Boehringer Ingelheim: A leader in the development of therapies for respiratory diseases, including idiopathic pulmonary fibrosis.
  • Roche: A global pharmaceutical company with a strong presence in immunology and oncology.
  • FibroGen: A biopharmaceutical company focused on fibrosis and hypoxia-inducible factor (HIF) biology.
  • United Therapeutics: A company specializing in therapies for pulmonary arterial hypertension and other rare diseases.

Despite the competition, aTyr differentiates itself through its unique focus on tRNA synthetase biology and its first-in-class therapeutic candidates.

Risk Factors

Like any biopharmaceutical company, aTyr Pharma faces several risks, including:

  • Regulatory Challenges: The development and approval of new drugs are subject to stringent regulatory requirements, which can delay or prevent commercialization.
  • Market Dependence: The company’s success is heavily dependent on the clinical and commercial success of efzofitimod and other pipeline candidates.
  • Supply Chain Disruptions: The global supply chain for biopharmaceuticals is complex and vulnerable to disruptions, which could impact aTyr’s operations.
  • Competition: The biopharmaceutical industry is highly competitive, with many companies vying for market share in similar therapeutic areas.
  • Financial Risks: As a clinical-stage company, aTyr relies on external funding to support its operations and may face challenges in securing additional capital.

Recent Developments

In recent years, aTyr Pharma has achieved several milestones:

  • Clinical Progress: The company has advanced efzofitimod into Phase 3 clinical trials for pulmonary sarcoidosis, with promising results from earlier studies.
  • Partnerships: aTyr has entered into collaborations with leading pharmaceutical companies, including Kyorin Pharmaceutical Co., Ltd., to develop and commercialize efzofitimod in Japan.
  • Scientific Discoveries: The company has made significant progress in understanding the role of tRNA synthetase biology in disease, paving the way for new therapeutic approaches.
  • Corporate Strategy: aTyr has streamlined its operations and focused its resources on high-priority programs to maximize efficiency and impact.

Investment Considerations

Investors considering aTyr Pharma should weigh the following factors:

Strengths

  • Innovative Science: aTyr’s focus on tRNA synthetase biology represents a unique and potentially transformative approach to drug development.
  • Strong Pipeline: The company has a promising pipeline of therapeutic candidates targeting high-value markets.
  • Experienced Leadership: aTyr’s management team has a proven track record in biopharmaceutical development and commercialization.

Risks

  • Clinical and Regulatory Uncertainty: The success of aTyr’s pipeline depends on the outcome of clinical trials and regulatory approvals.
  • Financial Dependence: The company relies on external funding and may face challenges in raising additional capital.
  • Market Competition: aTyr operates in a competitive industry with established players and emerging startups.

Conclusion

aTyr Pharma is a pioneering biopharmaceutical company with a unique focus on tRNA synthetase biology. The company’s innovative approach and promising pipeline position it as a leader in the development of novel therapeutics for severe diseases. While challenges remain, aTyr’s strong scientific foundation, strategic partnerships, and experienced leadership provide a solid platform for future growth. As the company advances its clinical programs and explores new therapeutic opportunities, it has the potential to make a significant impact on the biopharmaceutical industry and improve the lives of patients worldwide.